|
US3707475A
(en)
|
1970-11-16 |
1972-12-26 |
Pfizer |
Antiinflammatory imidazoles
|
|
DE3029376A1
(de)
|
1980-07-31 |
1982-03-18 |
Nepera Chemical Co. Inc., Harriman, N.Y. |
Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
|
|
DE3486009T2
(de)
|
1983-09-09 |
1993-04-15 |
Takeda Chemical Industries Ltd |
5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
|
|
JP2722586B2
(ja)
|
1989-01-13 |
1998-03-04 |
大正製薬株式会社 |
インドリルイミダゾール誘導体
|
|
JP2808460B2
(ja)
|
1989-11-16 |
1998-10-08 |
大正製薬株式会社 |
イミダゾール誘導体
|
|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
|
US5717100A
(en)
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
|
GB2306108A
(en)
|
1995-10-13 |
1997-04-30 |
Merck & Co Inc |
Treatment of Raf-mediated cancers with imidazole derivatives
|
|
EP0923579A1
(en)
|
1996-08-27 |
1999-06-23 |
Novartis AG |
Herbicidal s-substituted 1,2,4,6-thiatriazines
|
|
WO1998038984A2
(en)
|
1997-03-05 |
1998-09-11 |
Sugen, Inc. |
Formulations for hydrophobic pharmaceutical agents
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
GB9711650D0
(en)
|
1997-06-05 |
1997-07-30 |
Pfizer Ltd |
Compounds useful in therapy
|
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
WO2000042012A1
(en)
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
|
JP2002541253A
(ja)
|
1999-04-09 |
2002-12-03 |
スミスクライン・ビーチャム・コーポレイション |
トリアリールイミダゾール
|
|
MXPA01010292A
(es)
|
1999-04-15 |
2002-10-23 |
Squibb Bristol Myers Co |
Inhibidores ciclicos de la proteina tirosina cinasa.
|
|
JP2000302680A
(ja)
|
1999-04-23 |
2000-10-31 |
Takeda Chem Ind Ltd |
脳保護剤
|
|
EP1218358B1
(en)
|
1999-09-23 |
2006-09-13 |
AstraZeneca AB |
Therapeutic quinazoline compounds
|
|
ATE382044T1
(de)
|
1999-11-22 |
2008-01-15 |
Smithkline Beecham Plc |
Imidazol- derivate
|
|
WO2001052846A1
(en)
|
2000-01-18 |
2001-07-26 |
Vertex Pharmaceuticals Incorporated |
Gyrase inhibitors and uses thereof
|
|
CA2397686A1
(en)
|
2000-01-18 |
2001-07-26 |
Vertex Pharmaceuticals Incorporated |
Gyrase inhibitors and uses thereof
|
|
AR029803A1
(es)
|
2000-02-21 |
2003-07-16 |
Smithkline Beecham Plc |
Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
|
|
JP2003525936A
(ja)
|
2000-03-06 |
2003-09-02 |
スミスクライン ビーチャム パブリック リミテッド カンパニー |
Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体
|
|
GB0005357D0
(en)
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
|
GB0007405D0
(en)
|
2000-03-27 |
2000-05-17 |
Smithkline Beecham Corp |
Compounds
|
|
AU2001244618A1
(en)
|
2000-03-30 |
2001-10-15 |
Takeda Chemical Industries Ltd. |
Substituted 1,3-thiazole compounds, their production and use
|
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
|
US6949571B2
(en)
|
2000-06-12 |
2005-09-27 |
Eisai Co., Ltd. |
1,2-dihydropyridine compounds, process for preparation of the same and use thereof
|
|
SI1301472T1
(sl)
|
2000-07-19 |
2014-05-30 |
Warner-Lambert Company Llc |
Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin
|
|
JP2004514669A
(ja)
|
2000-11-07 |
2004-05-20 |
ブリストル−マイヤーズ スクイブ カンパニー |
セリンプロテアーゼ阻害剤として有用な酸誘導体
|
|
US20040053943A1
(en)
|
2000-11-20 |
2004-03-18 |
Adams Jerry L. |
Novel compounds
|
|
US7238813B2
(en)
|
2000-11-29 |
2007-07-03 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
JP4267920B2
(ja)
|
2001-01-26 |
2009-05-27 |
中外製薬株式会社 |
代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
|
|
EP1364949A4
(en)
|
2001-02-02 |
2005-11-23 |
Takeda Pharmaceutical |
JNK INHIBITOR
|
|
WO2002076960A1
(en)
|
2001-03-22 |
2002-10-03 |
Abbott Gmbh & Co. Kg |
Transition metal mediated process
|
|
JP2002338537A
(ja)
|
2001-05-16 |
2002-11-27 |
Mitsubishi Pharma Corp |
アミド化合物およびその医薬用途
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
GB0129260D0
(en)
|
2001-12-06 |
2002-01-23 |
Eisai London Res Lab Ltd |
Pharmaceutical compositions and their uses
|
|
US8299108B2
(en)
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
MXPA04009541A
(es)
|
2002-03-29 |
2005-01-25 |
Chiron Corp |
Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
|
|
AR039241A1
(es)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
|
OA12928A
(en)
|
2002-09-18 |
2006-10-13 |
Pfizer Prod Inc |
Novel imidazole compounds as transforming growth factor (TGF) inhibitors.
|
|
WO2004026863A1
(en)
|
2002-09-18 |
2004-04-01 |
Pfizer Products Inc. |
Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
|
|
US7531553B2
(en)
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
PE20050952A1
(es)
|
2003-09-24 |
2005-12-19 |
Novartis Ag |
Derivados de isoquinolina como inhibidores de b-raf
|
|
EP1673343A4
(en)
|
2003-10-08 |
2008-09-10 |
Irm Llc |
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
|
|
KR20060118472A
(ko)
|
2003-10-16 |
2006-11-23 |
카이론 코포레이션 |
치환 벤자졸 및 ｒａｆ 키나아제의 저해제로서 그것의 사용
|
|
CA2545942C
(en)
|
2003-11-14 |
2012-07-10 |
Lorus Therapeutics Inc. |
Aryl imidazoles and their use as anti-cancer agents
|
|
RU2367661C2
(ru)
|
2004-03-05 |
2009-09-20 |
Тайсо Фармасьютикал Ко., Лтд. |
Производные тиазола
|
|
KR100749566B1
(ko)
|
2004-04-21 |
2007-08-16 |
이화여자대학교 산학협력단 |
Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
|
|
US20060106020A1
(en)
|
2004-04-28 |
2006-05-18 |
Rodgers James D |
Tetracyclic inhibitors of Janus kinases
|
|
PE20060315A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de tiazol como moduladores de ppar
|
|
DE602005004286T2
(de)
|
2004-06-11 |
2009-01-02 |
Japan Tobacco Inc. |
5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
|
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415367D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JP2008511631A
(ja)
|
2004-08-31 |
2008-04-17 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール
|
|
WO2006038734A1
(en)
|
2004-10-08 |
2006-04-13 |
Astellas Pharma Inc. |
Pyridazinone derivatives cytokines inhibitors
|
|
EP1804801A2
(en)
|
2004-10-15 |
2007-07-11 |
Biogen Idec MA, Inc. |
Methods of treating vascular injuries
|
|
JP2007246520A
(ja)
|
2006-02-15 |
2007-09-27 |
Takeda Yuichiro |
Ｒａｇｅ阻害剤
|
|
US8217037B2
(en)
|
2006-04-07 |
2012-07-10 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
|
|
AU2007282535B9
(en)
|
2006-08-08 |
2013-06-20 |
Chugai Seiyaku Kabushiki Kaisha |
Pyrimidine derivative as PI3K inhibitor and use thereof
|
|
WO2008071605A2
(en)
|
2006-12-15 |
2008-06-19 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
RU2479580C2
(ru)
|
2007-06-27 |
2013-04-20 |
Астразенека Аб |
Производные пиразинона и их применение для лечения легочных заболеваний
|
|
CL2008001933A1
(es)
|
2007-06-29 |
2009-09-25 |
Millennium Pharm Inc |
Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
|
|
CA2694284A1
(en)
|
2007-06-29 |
2009-01-08 |
Jennifer Cossrow |
Heterocyclic compounds useful as raf kinase inhibitors
|
|
EP2176249A2
(en)
|
2007-07-02 |
2010-04-21 |
Boehringer Ingelheim International GmbH |
New chemical compounds
|
|
WO2009007749A2
(en)
|
2007-07-09 |
2009-01-15 |
Astrazeneca Ab |
Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
|
|
AU2008276063B2
(en)
|
2007-07-17 |
2013-11-28 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
|
EP2178861B1
(en)
|
2007-07-19 |
2014-08-20 |
Merck Sharp & Dohme Corp. |
Heterocyclic amide compounds as protein kinase inhibitors
|
|
WO2009032667A1
(en)
|
2007-08-29 |
2009-03-12 |
Smithkline Beecham Corporation |
Thiazole and oxazole kinase inhibitors
|
|
UY31322A1
(es)
|
2007-09-05 |
2009-04-30 |
|
Amidas heterocíclicas y sus métodos de uso-975
|
|
WO2009047163A1
(en)
|
2007-10-10 |
2009-04-16 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
TW200940537A
(en)
|
2008-02-26 |
2009-10-01 |
Astrazeneca Ab |
Heterocyclic urea derivatives and methods of use thereof
|
|
EA201001456A1
(ru)
|
2008-03-21 |
2011-06-30 |
Новартис Аг |
Новые гетероциклические соединения и их применение
|
|
US8865732B2
(en)
|
2008-03-21 |
2014-10-21 |
Novartis Ag |
Heterocyclic compounds and uses thereof
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
CA2726158A1
(en)
|
2008-06-11 |
2009-12-17 |
Dana Farber Cancer Institute |
Compounds and compositions useful for the treatment of malaria
|
|
DK2324008T3
(da)
|
2008-07-24 |
2012-07-23 |
Nerviano Medical Sciences Srl |
Diarylpyrazol som protein kinase inhibitorer
|
|
SI2331547T1
(sl)
|
2008-08-22 |
2014-11-28 |
Novartis Ag |
Pirolopirimidinske spojine kot CDK inhibitorji
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
NZ593969A
(en)
|
2008-12-19 |
2013-11-29 |
Vertex Pharma |
Pyrazine derivatives useful as inhibitors of atr kinase
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
AU2010291206A1
(en)
|
2009-09-04 |
2012-02-23 |
Novartis Ag |
Bipyridines useful for the treatment of proliferative diseases
|
|
WO2011059610A1
(en)
|
2009-11-10 |
2011-05-19 |
Glaxosmithkline Llc |
Benzene sulfonamide thiazole and oxazole compounds
|
|
US9315491B2
(en)
|
2009-12-28 |
2016-04-19 |
Development Center For Biotechnology |
Pyrimidine compounds as mTOR and PI3K inhibitors
|
|
EP2520575B1
(en)
|
2009-12-28 |
2016-11-30 |
General Incorporated Association Pharma Valley Project Supporting Organisation |
1,3,4-oxadiazole-2-carboxamide compound
|
|
KR20110123657A
(ko)
|
2010-05-07 |
2011-11-15 |
에스케이케미칼주식회사 |
피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
|
|
EA201201676A1
(ru)
|
2010-06-25 |
2013-06-28 |
Новартис Аг |
Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
|
|
US20130165456A1
(en)
|
2010-08-26 |
2013-06-27 |
Tona M. Gilmer |
Combination
|
|
CN101993415B
(zh)
|
2010-09-15 |
2013-08-14 |
北京韩美药品有限公司 |
作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
|
|
AR083797A1
(es)
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
|
SI2672967T1
(sl)
|
2011-02-07 |
2018-12-31 |
Plexxikon Inc. |
Spojine in postopki za kinazno modulacijo in indikacije zanjo
|
|
WO2013022766A1
(en)
|
2011-08-05 |
2013-02-14 |
Flynn Gary A |
Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
|
|
AP2014007493A0
(en)
|
2011-09-01 |
2014-03-31 |
Irm Llc |
Compounds and compositions as C-KIT kinase inhibitors
|
|
KR20140070616A
(ko)
|
2011-09-21 |
2014-06-10 |
셀좀 리미티드 |
Mtor 저해제로서의 모르폴리노 치환된 우레아 또는 카바메이트 유도체
|
|
EP2844655A1
(en)
|
2012-05-02 |
2015-03-11 |
Lupin Limited |
Substituted pyridine compounds as crac modulators
|
|
BR112014027181A2
(pt)
|
2012-05-15 |
2017-06-27 |
Novartis Ag |
derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
|
|
TW201414704A
(zh)
|
2012-07-02 |
2014-04-16 |
Biogen Idec Inc |
作爲ＲＯＲ－γ受體之反向促效劑之含聯芳化合物
|
|
AR091876A1
(es)
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
RS58734B1
(sr)
*
|
2012-08-07 |
2019-06-28 |
Novartis Ag |
Farmaceutske kombinacije koje obuhvataju b-raf inhibitor, egfr inhibitor i opciono pi3k-alfa inhibitor
|
|
CN107308164A
(zh)
|
2012-09-04 |
2017-11-03 |
诺华股份有限公司 |
辅助癌症治疗的方法
|
|
WO2014052699A1
(en)
|
2012-09-28 |
2014-04-03 |
Cephalon, Inc. |
Azaquinazoline inhibitors of atypical protein kinase c
|
|
EP2903613B1
(en)
|
2012-10-08 |
2017-11-22 |
Merck Sharp & Dohme Corp. |
Pyrazole derivatives useful as inhibitors of irak4 activity
|
|
WO2014097125A1
(en)
*
|
2012-12-20 |
2014-06-26 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
MY181085A
(en)
*
|
2013-03-21 |
2020-12-17 |
Novartis Ag |
Combination therapy
|
|
SI3063143T1
(sl)
*
|
2013-11-01 |
2018-09-28 |
Novartis Ag, |
Aminoheteroaril benzamidi kot inhibitorji kinaze
|
|
EP3082800B1
(en)
|
2013-12-20 |
2022-02-02 |
Biomed Valley Discoveries, Inc. |
Cancer treatment using combinations of erk and raf inhibitors
|
|
CN107001329B
(zh)
|
2014-09-12 |
2020-09-01 |
诺华股份有限公司 |
作为激酶抑制剂的化合物和组合物
|
|
EP3191478B1
(en)
|
2014-09-12 |
2019-05-08 |
Novartis AG |
Compounds and compositions as raf kinase inhibitors
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
WO2016115376A1
(en)
*
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Of California |
Detection and treatment of double drug resistant melanomas
|
|
CN108368171A
(zh)
|
2015-07-10 |
2018-08-03 |
根马布股份公司 |
用于癌症治疗的axl特异性抗体-药物缀合物
|
|
WO2017037575A1
(en)
*
|
2015-08-28 |
2017-03-09 |
Novartis Ag |
A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer
|
|
JP2018525425A
(ja)
|
2015-08-28 |
2018-09-06 |
ノバルティス アーゲー |
がんを治療または予防するためのリボシクリブとダブラフェニブの組み合わせ
|
|
FI3463345T3
(fi)
*
|
2016-06-03 |
2023-01-31 |
|
Farmaseuttisia yhdistelmiä
|
|
KR20190017767A
(ko)
*
|
2016-06-10 |
2019-02-20 |
노파르티스 아게 |
C-raf 억제제의 치료적 용도
|
|
EP3515446B1
(en)
*
|
2016-09-19 |
2023-12-20 |
Novartis AG |
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
|
|
US11590133B2
(en)
|
2016-12-11 |
2023-02-28 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for treatment of BRAF mutant cancers
|
|
WO2018203219A1
(en)
|
2017-05-02 |
2018-11-08 |
Novartis Ag |
Combination therapy
|
|
JP7405408B2
(ja)
|
2017-05-16 |
2023-12-26 |
バイオメッド バレー ディスカバリーズ，インコーポレイティド |
異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
|
|
TW202023556A
(zh)
|
2018-08-27 |
2020-07-01 |
美商庫拉腫瘤技術股份有限公司 |
以mapk路徑抑制劑治療腺癌
|
|
KR20210105388A
(ko)
|
2018-12-20 |
2021-08-26 |
노파르티스 아게 |
암 치료에서 사용하기 위한 raf 저해제와 cdk4/6 저해제를 이용하는 병용요법
|
|
US12187703B2
(en)
|
2019-05-13 |
2025-01-07 |
Novartis Ag |
Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer
|
|
US20230226030A1
(en)
|
2020-02-18 |
2023-07-20 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
|
|
EP4149472A1
(en)
|
2020-05-12 |
2023-03-22 |
Novartis AG |
Therapeutic combinations comprising a craf inhibitor
|